Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

SK Bioscience Bolsters Strategic Partnership with Novavax through Equity Investment

Wednesday, August 09, 2023

SK Bioscience announced to make an equity investment in Novavax to address endemic challenges.

SK bioscience and Novavax have prolonged their existing licence agreement to include Novavax's newly developed COVID-19 vaccine, designed for annual immunisation. This extended partnership also involves SK bioscience's exploration of future collaborations with Novavax, which will encompass leveraging Novavax's adjuvant, known as 'Matrix-M.'

The extended licence agreement will empower SK bioscience to set up a proactive response system within South Korea's vaccination landscape for the new endemic phase. This agreement is built on a successful partnership that has spanned multiple years, allowing both companies to understand each other's strengths.

As part of the agreement, SK bioscience secures exclusive distribution rights for Novavax's COVID-19 variant vaccine in South Korea, while also gaining non-exclusive distribution rights in Thailand and Vietnam for supply and commercialisation of the vaccine.

The strategic equity investment, combined with the collaboration between SK bioscience and Novavax throughout the pandemic, will create powerful synergy.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024